2,2'-DITHIODIETHANESULFONIC ACID

Summary

2,2’-Dithiodiethanesulfonic Acid (CHEMBL2009034) is a phase-3 clinical-stage small molecule targeting HTR1A, DRD2, and DRD3.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 7 (HTR1A, DRD2, DRD3…)
• Clinical trials: 1
• Chemistry: 282.4 Da · C4H10O6S4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2009034
Name	2,2’-DITHIODIETHANESULFONIC ACID
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	65626
Molecular formula	C4H10O6S4
Molecular weight	282.4
InChIKey	BYUKOOOZTSTOOH-UHFFFAOYSA-N

SMILES: C(CS(=O)(=O)O)SSCCS(=O)(=O)O

IUPAC name: 2-(2-sulfoethyldisulfanyl)ethanesulfonic acid

Also known as: 2,2’-dithiodiethanesulfonic acid, Dimesna, DIMESNA

Parent form; salt/anhydrous children: CHEMBL2028409, CHEMBL2104318

Patent coverage: 61 distinct patent families (161 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HTR1A	5-HT1A receptor	Full agonist	5.8	0%	P08908
DRD2	D2 receptor	Full agonist	7.7	0%	P14416
DRD3	D3 receptor	Full agonist	8	0%	P35462
DRD4	D4 receptor	Full agonist	7.5	0%	P21917
HTR2A	5-HT2A receptor	Full agonist	5.5	0%	P28223
HTR2B	5-HT2B receptor	Full agonist	6.5	0.4%	P41595
HTR2C	5-HT2C receptor	Full agonist	5.5	0%	P28335

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 7 target gene(s): HTR1A, DRD2, DRD3, DRD4, HTR2A, HTR2B, HTR2C.

Top Reactome pathways

10 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	4	HTR1A, HTR2A, HTR2B, HTR2C
Signaling by GPCR	4	HTR1A, HTR2A, HTR2B, HTR2C
Class A/1 (Rhodopsin-like receptors)	4	HTR1A, HTR2A, HTR2B, HTR2C
Amine ligand-binding receptors	4	HTR1A, HTR2A, HTR2B, HTR2C
Serotonin receptors	4	HTR1A, HTR2A, HTR2B, HTR2C
GPCR ligand binding	4	HTR1A, HTR2A, HTR2B, HTR2C
GPCR downstream signalling	3	HTR2A, HTR2B, HTR2C
Dopamine receptors	3	DRD2, DRD3, DRD4
G alpha (q) signalling events	3	HTR2A, HTR2B, HTR2C
G alpha (i) signalling events	2	DRD3, DRD4

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	7
signal transduction	7
intracellular calcium ion homeostasis	6
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5
chemical synaptic transmission	5
G protein-coupled serotonin receptor signaling pathway	5
serotonin receptor signaling pathway	4
response to xenobiotic stimulus	4
behavioral response to cocaine	4
release of sequestered calcium ion into cytosol	4
positive regulation of ERK1 and ERK2 cascade	4
behavioral fear response	3
positive regulation of cell population proliferation	3
adult behavior	3
adenylate cyclase-inhibiting dopamine receptor signaling pathway	3

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00003569	Not specified	COMPLETED	Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

838 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
Fidaxomicin	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
Propoxyphene	ChEMBL + PubChem	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
AMOXAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
APOMORPHINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
ASENAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
BENPERIDOL	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
CARIPRAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
CARVEDILOL	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
CLOZAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
DESLORATADINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
DOXEPIN	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
EBASTINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
HALOPERIDOL	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
ILOPERIDONE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
IMIPRAMINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
IPRINDOLE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
KETANSERIN	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
LOXAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
MIANSERIN	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
NEFAZODONE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
OLANZAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
PERGOLIDE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
PIMOZIDE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
PROMAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
PROMETHAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
QUETIAPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
RISPERIDONE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
SALMETEROL	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
SERTINDOLE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
SUNITINIB	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
TEGASEROD	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
THIORIDAZINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
THIOTHIXENE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
TRAZODONE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
ZIPRASIDONE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
LISURIDE	ChEMBL	Phase 3	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
LYSERGIDE	ChEMBL	Phase 2	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
NEMONAPRIDE	ChEMBL	Phase 2	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
PENFLURIDOL	ChEMBL	Phase 2	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
SPIPERONE	ChEMBL	Phase 2	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
ZOTEPINE	ChEMBL	Phase 2	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
Pyrazinamide	PubChem	Approved	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C
AMIODARONE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR2A, HTR2B, HTR2C
AMLODIPINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR2C
BUSPIRONE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR2C
CABERGOLINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR2C
CINACALCET	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR2C
CISAPRIDE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR2C
CLEMASTINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR2C
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR2C